INmune Bio, Inc. (INMB) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boca Raton, FL, アメリカ. 現CEOは David J. Moss.
INMB を有する IPO日 2019-02-04, 13 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $35.09M.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
